Phase II, Open-Label Study of Encorafenib Plus Binimetinib in Patients with BRAF V600-Mutant Metastatic Non-Small-Cell Lung Cancer
- Gregory J. Riely
- , Egbert F. Smit
- , Myung Ju Ahn
- , Enriqueta Felip
- , Suresh S. Ramalingam
- , Anne Tsao
- , Melissa Johnson
- , Francesco Gelsomino
- , Raymond Esper
- , Ernest Nadal
- , Michael Offin
- , Mariano Provencio
- , Jeffrey Clarke
- , Maen Hussain
- , Gregory A. Otterson
- , Ibiayi Dagogo-Jack
- , Jonathan W. Goldman
- , Daniel Morgensztern
- , Ann Alcasid
- , Tiziana Usari
- Memorial Sloan-Kettering Cancer Center
- Leiden University
- Vall d'Hebron Institute of Oncology
- Emory University
- University of Texas MD Anderson Cancer Center
- Sarah Cannon Research Institute
- University Hospital S. Orsola
- Florida Cancer Specialists
- Institute Catala Oncologia
- Hospital Universitario Puerta de Hierro Majadahonda
- Duke University
- Ohio State University
- Massachusetts General Hospital
- University of California at Los Angeles
- Washington University St. Louis
- Pfizer
- Pfizer
- Dana-Farber Cancer Institute
Research output: Contribution to journal › Article › peer-review
97
Link opens in a new tab
Scopus
citations